REG - Mast Energy Dvlpmts. - JV & Investment. New Broker & Loan Reprofiling

Mast Energy DevelopmentsAnnouncement

18/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230518:nRSR8049Za&default-theme=true

RNS Number : 8049Z  Mast Energy Developments PLC  18 May 2023

Mast Energy Developments PLC

(Incorporated in England and Wales)

(Registration Number: 12886458)

Share code on the LSE: MAST

ISIN: GB00BMBSCV12

('MED' or 'the Company')

 

Dated: 18 May 2023

 

Mast Energy Developments PLC ('MED' or 'the Company')

 

MED Announces Joint Venture and associated Significant Investment, Appointment
of New Corporate Broker, and Reprofiling of its Loan Facilities

 

Mast Energy Developments PLC, the UK-based multi-asset owner, developer, and
operator in the rapidly growing flexible power market, is pleased to announce
that it has recently concluded a Heads of Terms ('HoT') with regard to a new
Joint Venture ('JV') agreement between MED and a new institutional
investor-led consortium (the 'Institutional Investor'). Under the HoT, it is
envisaged that the Institutional Investor will inject all required investment
capital into the JV with an expected total investment value of c. £33.6m,
with no funding contribution required from MED. MED will be providing the
required projects to the JV, for a total portfolio of gas peaker plants with a
combined generation output of c. 50 MW to be developed and/or acquired,
constructed and in production and income generating within the next 12 months.
An overview of the key highlights and terms of the JV are provided below.

 

Further, MED announces the appointment of Novum Securities Limited ("Novum")
as corporate broker to the Company. Novum will be taking over from Clear
Capital Markets Limited as sole broker with immediate effect.

 

Finally, MED announces that is has agreed to a reprofiling of the outstanding
balances on its existing loan facilities (herein referred to as the
'Acquisition Loan' and the 'Development Loan', and together as the 'Loans')
held through an institutional lender group (the 'Institutional Lender'). The
Loans' details were previously announced by the Company in RNSs dated 5
October 2022 and 3 November 2022, respectively. The current aggregate balance
outstanding on the Loans is £729,750 (the 'Reprofiled Balance'), which was
transferred to the new loan agreement (the 'Reprofiling Agreement') signed
between the Company and the Institutional Lender on 17 May 2023 (the
'Execution Date'). Under the terms of the Reprofiling Agreement, the
Reprofiled Amount is deemed an initial advance on the Execution Date.

 

JV Key Highlights

 

The key terms of the JV agreement comprise the following:

 

·    Institutional Investor will inject all required investment capital
into the JV with an expected total investment value of c. £33.6m, with no
funding contribution required from MED.

·    Institutional Investor to hold 74.9% of the JV and MED to hold 25.1%,
subject to the Institutional Investor recognising and reimbursing to MED its
actual historic project acquisition and development related costs, totaling an
expected c. £7.7m, as detailed below, and no requirement on MED to provide
any further funding.

·    MED will have joint control of the JV SPV Board and full operational
control of the projects' management and operations.

·    Upon execution of the JVA, at Investment Tranche 1, consisting of
three projects with a combined generation capacity of a minimum 26.5 MW that
MED will provide to the JV, the Institutional Investor will then pay MED c.
£3.7m as part repayment of the historic project acquisition and development
related costs and inject c. £11m into the JV SPV to cover future capex on
these projects.

·    Upon satisfactory completion of Investment Tranche 1, at Investment
Tranche 2, consisting of three projects with a combined generation capacity of
a minimum 14 MW and up to 30 MW that MED will provide to the JV, the
Institutional Investor will then pay MED c. £4m as part repayment of the
historic project acquisition and development related costs and inject c. £15m
into the JV SPV to cover future capex on these three projects.

·    The Institutional Investor will receive a preferential entitlement to
90% of the profit of the JV until the investment provided under part (i) of
the Investment Tranche's 1 & 2 has been recovered in full, at which point
any distribution of profits will return to the equity split.

·    Therefore, MED will, assuming it can provide the projects as
required, receive a c. 25% free stake in a portfolio of around c. 50 MW of
assets that will be fully funded, constructed and revenue generating within
the next 12 months.

·    It is expected that upon completion of both Investment Tranches 1 and
2, the total expected average annual revenue to be generated by the associated
assets in the JV portfolio will comprise c. £15m per annum.

·    In addition, the JV will grant MED a five-year management services
agreement ('MSA') and associated fee to manage the sites, which will further
bolster MED's share of income from the JV.

·    It is MED's intention and plan to use the proceeds from the JV
investment tranches to further bolster its own wholly owned portfolio of
assets (outside of the JV), by way of further development, construction and
new acquisitions.

·    The HoT is subject to a typical confirmatory due diligence to the
satisfaction of both parties, concluding the associated definitive JV
agreement and any regulatory and Board approvals.

·    All JV deal numbers quoted herein are indicative and subject to the
concluding of a definitive JV agreement.

·    It is expected that the JV agreement will be completed and executed
around mid-June 2023 but there is no guarantee that a definitive agreement
will be reached.

 

Second Drawdown on Development Loan

 

The Reprofiled Amount includes the aggregate outstanding principal and accrued
interest amounts of £729,750 on the Loans, and the proceeds of a Second
Advance under the terms of the Development Loan of £100,000 availed by the
Company in conjunction with the signing of the Reprofiling Agreement on the
Execution Date. The proceeds accruing from the Second Advance will be used by
the Company for ongoing project development costs.

 

Details of the Reprofiling Agreement

 

The terms of repayment for the Reprofiled Balance (the 'Deemed Advance') and
any additional subsequence drawdowns ('Further Advances') under the
Reprofiling Agreement, comprise the following:

 

·    The Reprofiled Balance will be subject to a six-month principal
repayment holiday, followed by 18 equal monthly cash repayments of principal
and the coupon thereafter on the maturity date, which falls 24 months from the
Execution Date. It is noted that the first drawdown (or Deemed Advance) is the
Reprofiled Balance, and the first drawdown date is the Execution Date. Further
Advances will be the subject of mutual agreement between the Institutional
Lender and the Company for the duration of the Commitment Period (defined as
three (3) years from the Execution Date).

·    The Institutional Lender may elect to avail of the following MED
share conversions (a 'Conversion') during the duration of the Commitment
Period:

o During the first 12-month period following the Execution Date, it can
convert 50% of the Reprofiled Balance plus applicable interest to MED ordinary
shares at the lower of (a) a deemed price of £0.02 per MED share or (b) at
the last Company share placing price for any third-party equity fundraising
carried out prior to a Conversion during this period (the 'Fixed Price');

o After the initial 12 months, during the Term, the Institutional Lender may
elect to convert any outstanding amount on the Reprofiling Agreement at the
Fixed Price; or

o If the Company elects not to settle a monthly payment (each being a
'Unsettled Payment'), they will automatically grant a right for the monthly
payment to be settled in shares, being that the lender will be granted
subscription rights over such balances for a period ending on the later of (a)
the remaining 24 months from the relevant drawdown date and (b) 12 months from
the unsettled payment date, to convert the relevant Unsettled Payments to MED
shares at 90 per cent of the one daily volume-weighted average price ('VWAP')
of MED shares chosen by the Institutional Lender in respect of MED shares
traded on the LSE during the 10 trading days immediately preceding the date of
a share conversion notice with respect to the Unsettled Repayment. At the
expiry of the Convertible Period, the portion of the Elected Unsettled Payment
not redeemed will be paid to the Institutional Lender.

·    The Company will grant senior fixed and floating security over its
assets by way of debenture, save to the extent that any relevant MED Project
SPV subsidiary companies that will be party to the above referred JV agreement
being currently considered by the Company will be excluded, provided the
monies due to the Institutional Lender from the Company is reduced to the
aggregate of £300,000, which the Company is permitted to do pursuant to the
terms of the agreement or otherwise waived by the Institutional Lender.

·    The Reprofiled Balance will be subject to a 9.5% fixed coupon over
the 24-month term, such calculation being made for each annual period at the
commencement of the relevant 12-month period.

 

Warrant Issue

 

The Institutional Lender has also been issued warrants under the terms of the
Development Loan and the Reprofiling Agreement as follows:

 

Development Loan: 4,511,312 warrants calculated as 40% of the Second Advance
divided by the Reference Price of £0.0088666 (being the average of the five
(5) daily VWAPs preceding the Execution Date. The warrants are exercisable at
130% of the Reference Price, save that, in the event that the Issuer completes
any share placing during the term of the Second Advance and the share placing
price is below 130% of the Reference Price, the exercise price will be the
share placing price. The exercise period is 36 months from the date of the
grant.

 

Reprofiling Agreement: 82,303,250 warrants calculated as 100% of the
Reprofiled Balance of the £729,750 divided by the Reference Price of
£0.0088666 (being the average of the five (5) daily VWAPs prior to the
Execution Date) and issued on or before the 30 July 2023. Half of the warrants
will be exercisable at the relevant Reference Price and the other half will be
exercisable at 200% of the relevant Reference Price. The exercise period will
be 48 months from the date of issue.

 

The details of warrants to be issued for Further Advances will be agreed
between the Institutional Lender and the Company at the time.

 

The exercise of the warrants may be offset against outstanding balances
pursuant to the Reprofiling Agreement.

 

Pieter Krügel, CEO of MED, commented: "We are very pleased to have signed a
HoT with regards to the JV deal and excited to conclude the JV agreement in
due course. The JV, outside of MED's own wholly owned portfolio of assets
which we will continue to grow in parallel, will not only provide MED with a
significant cash injection but also a significant stake in a portfolio of
assets totaling an expected 50 MW that will be fully funded, constructed, in
production and income generating in the next 12 months. MED's share of income
from the JV portfolio revenue, and in addition its 5-year MSA fee, will
provide MED with a significant long-term recurring income stream. The JV deal
has been long in the making and follows a robust initial due diligence and
negotiation process. The willingness of the Institutional Investor-led
consortium to enter into the HoT with MED is testament of their confidence in
the Company's strategy and long-term development plans to deliver flexible
energy projects that are commercially viable.

 

Further, we are pleased with the appointment of Novum as sole broker and to
have Novum as a strategic partner to the MED-team.

 

Finally, we are pleased to have reached agreement with the Institutional
Lender to implement the reprofiling of the existing loans and to secure a
further funding advance. The reprofiling of the loans will simplify MED's
repayment obligations and provide a meaningful runway to ensure the Company's
financial and operational stability and to support its development plans."

 

ENDS

This announcement contains inside information for the purposes of the UK
version of the Market Abuse Regulation (EU No. 596/2014) as it forms part of
United Kingdom domestic law by virtue of the European Union (Withdrawal) Act
2018 ('UK MAR'). Upon the publication of this announcement, this inside
information is now considered to be in the public domain.

 

For further information please visit www.med.energy (http://www.med.energy/)
or contact:

 

 Pieter Krügel                 Info@med.energy (mailto:Info@med.energy)                              Mast Energy          CEO

                                                                                                     Developments PLC
 Jon Belliss                   +44 (0)20 7399 9425                                                   Novum Securities     Corporate Broker
 Zainab Slemang van Rijmenant  zainab@lifacommunications.com (mailto:zainab@lifacommunications.com)  Lifa Communications  Investor & Media Relations Advisor

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDBGDUUSBDGXR